Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.44 |
| ▸ | FEN1 | P39748 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23558653 | 0.86 | GPR119 (0.50) | GPR119 | |
| SCHEMBL20936874 | 0.84 | NR1H2 (0.52) | GPR119 | |
| SCHEMBL24608255 | 0.84 | NR1H2 (0.52) | GPR119 | |
| SCHEMBL23545096 | 0.84 | NR1H2 (0.52) | GPR119 | |
| SCHEMBL22797267 | 0.84 | OXTR (0.42) | GPR119 | |
| SCHEMBL4979209 | 0.83 | CHRNB2 (0.42) | — | |
| SCHEMBL5266887 | 0.82 | GPR119 (0.65) | GPR119 | |
| SCHEMBL25401294 | 0.82 | GPR119 (0.44) | GPR119 | |
| SCHEMBL3842144 | 0.82 | GRIN2B (0.43) | GPR119 | |
| SCHEMBL20642053 | 0.82 | GPR119 (0.50) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11325896-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2022-05-10 | — | — | US | disclosed |
| US-20200392117-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2020-12-17 | — | — | US | disclosed |
| EP-2858986-B1 | PIPERIDINE DERIVATIVES AS GPR119 AGONISTS | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2019-10-30 | — | — | EP | disclosed |
| US-9944600-B2 | Piperidine derivatives for GPR119 agonist | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2018-04-17 | — | — | US | disclosed |
| US-20150166480-A1 | PIPERIDINE DERIVATIVES FOR GPR119 AGONIST | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2015-06-18 | — | — | US | disclosed |
| EP-2858986-A1 | PIPERIDINE DERIVATIVES FOR GPR119 AGONIST | Chong Kun Dang Pharmaceutical Corp. (KR) | 2015-04-15 | — | — | EP | disclosed |
| WO-2013187646-A1 | PIPERIDINE DERIVATIVES FOR GPR119 AGONIST | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2013-12-19 | — | — | WO | disclosed |
| US-20120077812-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | FANG JING (US) | 2012-03-29 | — | — | US | disclosed |
| US-8101634-B2 | Bicyclic compounds and use as antidiabetics | GLAXOSMITHKLINE LLC (US) | 2012-01-24 | — | — | US | disclosed |
| EP-2325182-A1 | Bicyclic compounds and use as antidiabetics | Glaxosmithkline LLC (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20100029650-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SMITH KLINE BEECHAM CORPORATION a corporation | 2010-02-04 | — | — | US | disclosed |
| EP-2094683-A2 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SmithKline Beecham Corporation (US) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008070692-A2 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | WO | disclosed |
| US-20080058339-A1 | New compounds | BIOVITRUM (SE) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077812-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | GPR119, GOT2, PC | KDM4E 4189/4885PKM 910/4885GPR119 1/4885 |
| US-20080058339-A1 | New compounds | GPR119, GPR180, GPR139 | KDM4E 4707/4885PKM 3340/4885GPR119 1/4885 |
| US-20200392117-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM2, CHRM3, CHRM4 | KDM4E 2050/4885PKM 3774/4885GPR119 91/4885 |
| US-20150166480-A1 | PIPERIDINE DERIVATIVES FOR GPR119 AGONIST | GPR119, FFAR2, GPR84 | KDM4E 2033/4885PKM 1965/4885GPR119 1/4885 |
| US-11325896-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | CHRM2, CHRM3, CHRM5 | KDM4E 2206/4885PKM 3804/4885GPR119 54/4885 |
| US-20100029650-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | GPR119, GOT2, PC | KDM4E 4189/4885PKM 910/4885GPR119 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.